^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cisplatin

    i
    Other names: L01XA01, L01 XA01, L01-XA01
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1d
    Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer (clinicaltrials.gov)
    P1/2, N=29, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P1/2 trial
    |
    cisplatin • Jingzhuda (entinostat)
    1d
    Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) (clinicaltrials.gov)
    P3, N=89, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • 5-fluorouracil • epacadostat (INCB024360)
    1d
    NRG-LU005: Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov)
    P3, N=544, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2029
    Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV
    1d
    FAM172A promotes epithelial ovarian cancer progression and induces platinum resistance via the PI3K/AKT pathway. (PubMed, Sci Rep)
    In vitro, FAM172A promoted malignant behavior and conferred resistance to cisplatin...These findings highlight FAM172A as a critical promoter of EOC progression, associated with aggressive tumor characteristics and treatment failure. By activating the PI3K-Akt pathway, FAM172A represents a promising therapeutic target for EOC, potentially offering new strategies to improve patient outcomes, particularly in overcoming chemoresistance.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    cisplatin
    1d
    Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC (clinicaltrials.gov)
    P2, N=318, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Jan 2025 --> Jun 2025
    Trial initiation date • Real-world evidence
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    1d
    TROPION Lung15: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=744, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Jun 2026 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk)
    1d
    6-gingerol alleviates chemotherapy-induced nausea and vomiting by inhibiting ferroptosis via the regulation of iron homeostasis. (PubMed, Cancer Chemother Pharmacol)
    Overall, this study indicates that regulating iron homeostasis to inhibit ferroptosis is related to the therapeutic effect of 6-gingerol against CINV.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TFRC • IL1B (Interleukin 1, beta) • DMRT1 (Doublesex And Mab-3 Related Transcription Factor 1)
    |
    cisplatin
    1d
    Clinical Efficacy and Safety of Gemcitabine-Cisplatin Combination in Metastatic Gallbladder Cancer: A Prospective Study from North India. (PubMed, J Gastrointest Cancer)
    Gemcitabine-cisplatin remains effective and tolerable in metastatic GBC. Despite the emergence of Gemcitabine-Cisplatin with durvalumab as new standard, this prospective dataset provides valuable real-world outcomes from a high-incidence region with limited access to immunotherapy.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    1d
    Co-Delivery of Cisplatin and Curcumin via ROS-Responsive Nanoparticles to Activate the cGAS-STING Pathway for Osteosarcoma Metalloimmunotherapy. (PubMed, Adv Healthc Mater)
    RNA sequencing analysis demonstrated that NP3 synergistically promoted tumor regression by concurrently inducing pro-apoptotic signaling and immune responses. In conclusion, this study presents an innovative therapeutic strategy combining targeted chemotherapy delivery with robust antitumor metalloimmunotherapy, offering a promising therapeutic approach for OS.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    cisplatin
    2d
    JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=119, Completed, Shanghai Junshi Bioscience Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • Loqtorzi (toripalimab-tpzi) • pemetrexed • etoposide IV • tifcemalimab (TAB004)
    2d
    A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (clinicaltrials.gov)
    P3, N=1023, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Jiataile (sacituzumab tirumotecan)
    2d
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. (clinicaltrials.gov)
    P1/2, N=202, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P1/2 trial
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • YL201